These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9467039)

  • 21. Trimetrexate: review and current clinical experience in advanced colorectal cancer.
    Blanke CD; Messenger M; Taplin SC
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-57-S18-63. PubMed ID: 9420022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biochemical modulation of 5-fluorouracil by high-dose leucovorin].
    Aiba K
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):392-408. PubMed ID: 3279911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration.
    Zhang ZG; Harstrick A; Rustum YM
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):10-5. PubMed ID: 1532669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B; Luis R; Jaime M; Franceschi D
    Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
    Cao S; Frank C; Rustum YM
    J Natl Cancer Inst; 1996 Apr; 88(7):430-6. PubMed ID: 8618234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison between leucovorin and cisplatin as a modulator of 5-fluorouracil].
    Iba T; Yagi Y; Kidokoro A; Fukunaga T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):479-83. PubMed ID: 8452385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of various strategies to enhance the cytotoxic activity of 5-fluorouracil/leucovorin in human colorectal cancer cell lines.
    Scheithauer W; Temsch EM
    Anticancer Res; 1989; 9(6):1793-8. PubMed ID: 2627128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms.
    Zhang ZG; Rustum YM
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):46-50. PubMed ID: 1532459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma.
    Rustum YM
    Chemioterapia; 1985 Oct; 4(5):377-82. PubMed ID: 3878232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leucovorin modulation of fluorouracil.
    Grogan L; Sotos GA; Allegra CJ
    Oncology (Williston Park); 1993 Aug; 7(8):63-72; discussion 75-6. PubMed ID: 8398636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experimental study of biochemical modulation of 5-fluorouracil with l-leucovorin against human esophageal cancer].
    Terashima M; Ikeda K; Kawamura H; Maesawa C; Takiyama I; Yoshinari H; Koeda K; Sato N; Ishida K; Saito K
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1999-2004. PubMed ID: 1417007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
    Köhne-Wömpner CH; Schmoll HJ; Harstrick A; Rustum YM
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):105-25. PubMed ID: 1373004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cao S; Rustum YM; Spector T
    Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
    Sotos GA; Grogan L; Allegra CJ
    Cancer Treat Rev; 1994 Jan; 20(1):11-49. PubMed ID: 7507404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on biochemical modulation of chemotherapeutic agents.
    Kobayashi K; Schilsky RL
    Oncology (Williston Park); 1993 May; 7(5):99-106, 109; discussion 110-4, 117. PubMed ID: 8512789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
    Benz C; Tillis T; Tattelman E; Cadman E
    Cancer Res; 1982 May; 42(5):2081-6. PubMed ID: 6175406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-FU/leucovorin: biochemical modulation that works?
    Arbuck SG
    Oncology (Williston Park); 1987 Apr; 1(2):61-74. PubMed ID: 3079477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of 5-FU action by thymidine in murine and human tumors.
    Young CW; Woodcock TM; Martin DS
    Cancer Treat Rep; 1981; 65 Suppl 3():83-7. PubMed ID: 7346156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells.
    Romanini A; Li WW; Colofiore JR; Bertino JR
    J Natl Cancer Inst; 1992 Jul; 84(13):1033-8. PubMed ID: 1376779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin.
    Rustum YM; Trave F; Zakrzewski SF; Petrelli N; Herrera L; Mittelman A; Arbuck SG; Creaven PJ
    NCI Monogr; 1987; (5):165-70. PubMed ID: 2448653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.